SEC Form 4 · accession 0001562180-18-000727
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Director
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2018 | M | 25,000 | $5.95 | A | 35,000 | D | |
| Common Stock | Feb 9, 2018 | M | 25,000 | $5.13 | A | 60,000 | D | |
| Common StockF1 | Feb 9, 2018 | S | 50,000 | $16.90 | D | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.95 | Feb 9, 2018 | M | 25,000 | D | Oct 27, 2017 | Oct 27, 2026 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy) | $5.13 | Feb 9, 2018 | M | 25,000 | D | Oct 29, 2016 | Oct 29, 2025 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.